The women’s healthcare market is expected to grow at a CAGR of ~9.78% from 2020 to reach USD 19.8 billion by 2027. The growth of this market is driven by the increasing prevalence of chronic health disorders among women, research & development for advanced products for women’s health, government initiatives to control population and awareness around prevention of unwanted pregnancies.
By Drug: Proila accounted for largest market share in 2020
The women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL and ORTHO TRI-CY LO (28) on the basis of drug. Prolia is expected to account for largest market share among all drugs used in Women’s healthcare. The large share is mainly attributed to use of this drug in postmenopausal osteoporosis and growing population of older women across the globe.
By Application: Postmenopausal osteoporosis accounted for largest share in 2020
Based on the application, women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, polycystic ovary syndrome, and other applications. Post-menopausal osteoporosis accounted for largest share in 2020. The growth can mainly be ascribed by the growing geriatric population leading to prevalence of postmenopausal osteoporosis and osteoporosis fractures, prevalence of obesity in women and introduction of various related drugs to cure menopausal osteoporosis.
By Region: APAC Fastest Growing Regional Market
North America accounted for largest market share for women’s healthcare market. The prevalence of poly cystic ovary syndrome and postmenopausal osteoporosis in the population of North America, increased expenditure on women’s health by governments are major factor accounting for the large share. APAC is expected to grow at highest CAGR. The growth is mainly driven by rising awareness, prevalence of disorders such as infertility, osteoarthritis and other related diseases in women.
Key Players
The major players operating in the global women’s healthcare market are
Bayer AG (Germany)
Allergan (Dublin)
Merck & Co. (US)
Pfizer Inc. (US)
Amgen (US)
Agile Therapeutics Inc. (US)
Ferring Pharmaceuticals (US)
Mylan N.V. (US)
Lupin (India)
Blairex Laboratories (US)
Apothecus Pharmaceutical (US)
Eli Lilly And Company (US)
Novartis AG (Switzerland)
Johnson & Johnson (US)
'
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
1) Introduction
2) Market Dynamics
i. Drivers
ii. Restraints
iii. Opportunities
iv. Challenges
3) COVID-19 Impact of the Women’s Healthcare Market
5. Industry Insights
1) Introduction
2) Industry Trends
6. Global Women’s Healthcare Market, By Drug, 2019-2027 (USD Million)
1) EVISTA
2) XGEVA
3) Prolia
4) Mirena
5) Zometa
6) Reclast/Aclasta
7) Minastrin 24 Fe
8) NuvaRing
9) FORTEO
10) Premarin
11) ACTONEL
12) ORTHO TRI-CY LO (28)
7. Global Women’s Healthcare Market, By Application, 2019-2027 (USD Million)
1) Hormonal Infertility
2) Postmenopausal Osteoporosis
3) Endometriosis
4) Contraceptives
5) Menopause
6) Polycystic Ovary Syndrome
7) Other Applications
8. Global Women’s Healthcare Market, By Geography, 2019-2027 (USD Million)
1) North America
i. US
ii. Canada
2) Europe
i. Germany
ii. UK
iii. France
iv. Italy
v. Spain
vi. Rest of Europe
3) Asia-Pacific
i. China
ii. Japan
iii. India
iv. Rest of Asia-Pacific
4) Rest of the world
i. Latin America
ii. Middle East and Africa
9. Competitive Landscape
1) Introduction
2) Market Share Analysis
3) Competitive Situation and Trends
i. Product Launches
ii. Partnerships, Collaborations, and Agreements
iii. Acquisitions
iv. Expansions
v. Other Developments
10. Company Profiles
1) Bayer AG (Germany)
2) Allergan (Dublin)
3) Merck & Co. (US)
4) Pfizer Inc. (US)
5) Amgen (US)
6) Agile Therapeutics Inc. (US)
7) Ferring Pharmaceuticals (US)
8) Mylan N.V. (US)
9) Lupin (India)
10) Blairex Laboratories (US)
11) Apothecus Pharmaceutical (US)
12) Eli Lilly And Company (US)
13) Novartis AG (Switzerland)
14) Johnson & Johnson (US)
11. Appendix
